Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Pfizer Inc. (PFE) reported Q2 FY 2022 earnings results that solidly surpassed analyst expectations. Adjusted earnings per share (EPS) surged by 92.5% relative to the year-ago quarter, beating ...

Pfizer (PFE) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $2.04 per share a year ago. These figures ...

Pfizer Inc. (NYSE:PFE) Q2 2024 Earnings Conference Call July 30, 2024 10:30 AM ETCompany ParticipantsFrancesca DeMartino – Chief Investor Relations Officer ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets.

Pfizer PFE reported second-quarter 2024 adjusted earnings per share of 60 cents, which comfortably beat the Zacks Consensus Estimate of 45 cents per share. Earnings declined 11% year over year due ...

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

Pfizer Inc. raised the lower end of its earnings forecast for the year and reiterated its sales expectations despite unfavorable currency trends. The drugmaker continues to project its new Covid ...

PFE’s FY24 Outlook Looking forward, Pfizer raised its FY24 forecast by $1 billion to be in the range of $59.5 billion to $62.5 billion and raised its adjusted earnings guidance by $0.30 to be ...

Pfizer Inc. (NYSE:PFE) Q2 2023 Results Conference Call August 1, 2023 10:00 AM ETCompany ParticipantsChris Stevo - SVP and Chief IR OfficerDr.

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.